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Abstract
Oral antiviral agents to treat influenza are challenging to administer in the intensive care unit (ICU). We describe 57 critically
ill patients treated with the investigational intravenous neuraminidase inhibitor drug peramivir for influenza A
(H1N1)pdm09 [pH1N1]. Most received late peramivir treatment following clinical deterioration in the ICU on enterically-
administered oseltamivir therapy. The median age was 40 years (range 5 months-81 years). Common clinical complications
included pneumonia or acute respiratory distress syndrome requiring mechanical ventilation (54; 95%), sepsis requiring
vasopressor support (34/53; 64%), acute renal failure requiring hemodialysis (19/53; 36%) and secondary bacterial infection
(14; 25%). Over half (29; 51%) died. When comparing the 57 peramivir-treated cases with 1627 critically ill cases who did not
receive peramivir, peramivir recipients were more likely to be diagnosed with pneumonia/acute respiratory distress
syndrome (p=0.0002) or sepsis (p=,0.0001), require mechanical ventilation (p=,0.0001) or die (p=,0.0001). The high
mortality could be due to the pre-existing clinical severity of cases prior to request for peramivir, but also raises questions
about peramivir safety and effectiveness in hospitalized and critically ill patients. The use of peramivir merits further study in
randomized controlled trials, or by use of methods such as propensity scoring and matching, to assess clinical effectiveness
and safety.
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Introduction
The influenza A(H1N1)pdm09 [pH1N1] virus emerged in April
2009 to cause a global pandemic [1–3]. In California, the reported
morbidity and mortality were high, with 2042 persons admitted to
intensive care units (ICU); 609 were fatal.
Early in the pandemic, the only available antiviral drugs for
treatment of pH1N1 were the neuraminidase inhibitors (NAI), oral
oseltamivir or inhaled zanamivir. Administration of enterically-
administered oseltamivir can be challenging in the ICU where
patients may have difficulty tolerating oral administration of
capsules or intestinal ileus may cause malabsorption [4]. Use of
inhaled zanamivir is not formulated for use in patients on
mechanical ventilation [2]. As part of the emergency public health
response, on November 19, 2009 the Commissioner of the Food
and Drug Administration issued an Emergency Use Authorization
(EUA) for the experimental intravenous (IV) NAI drug peramivir.
Under the EUA, peramivir was distributed by the Centers for
Disease Control and Prevention (CDC) for treatment of hospital-
ized pediatric and adult patients with evidence of pH1N1 virus
infection and who 1) were not responding to antiviral therapy, or
2) the clinician deemed that enteral or inhaled delivery of NAIs
was not dependable or feasible [5].
In April 2009, the California Department of Public Health
(CDPH) initiated mandatory reporting for critically ill and fatal
cases of pH1N1. In this report, we describe the epidemiology,
clinical characteristics, and outcomes of pH1N1 cases reported to
CDPH who received IV peramivir during the pandemic.
Methods
This study protocol was reviewed and approved by the State of
California Committee for the Protection of Human Subjects
(CPHS). A waiver of informed consent was granted as the data
were collected as part of public health practice and were analyzed
anonymously, the risk to subjects was minimal, the rights and
welfare of subjects were not adversely affected, and the research
could not have been practically carried out without a waiver
(Common Rule 45 CFR 46.11).
A case was defined as a California resident who was hospitalized
in an ICU for $24 hours with signs and symptoms consistent with
acute respiratory infection and laboratory evidence of pH1N1
virus infection by reverse-transcription polymerase chain reaction
(RT-PCR). Cases were reported by providers, hospitals and
county coroners to local health jurisdictions (LHJ) who subse-
quently reported them to CDPH. Data on demographics, clinical
presentation and hospital course, co-morbid conditions, dosing
and dates of antiviral medications administered were abstracted
from medical records, pharmacy medication records and autopsy
reports by staff at the LHJ or CDPH using the same standardized
case report form. Secondary bacterial co-infection was defined by
isolation of bacteria within 3 days of admission from either a sterile
site (e.g., blood, cerebrospinal fluid, or pleural fluid) or a lower
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endotracheal aspirate) in conjunction with new infiltrate on chest
radiograph.
Comparative analysis was performed for 1) critically ill patients
who received peramivir and critically ill patients who were treated
with NAIs but did not receive peramivir; and 2) fatal and non-fatal
peramivir-treated cases, with respect to demographics, clinical
characteristics, and underlying risk factors; differences in categor-
ical variables were analyzed using the chi-square test for
comparisons of categorical variables with large numbers and the
Fisher’s exact test for comparisons of categorical variables with
numbers ,5. All analyses were performed using SAS 9.2 (SAS
Institute, Cary, NC).
Results
During April 3, 2009 – August 10, 2010, 1962 California
residents were reported with pH1N1 virus infection that were
hospitalized $24 hours and required intensive care. Information
on whether or not antiviral treatment was given was available in
1867 (95%) cases; of these, 1684 (90%) received treatment with an
NAI.
Fifty-seven (3%) cases received IV peramivir (Table 1). Fifty-two
of these cases received oseltamivir as a second antiviral, and
another five cases were treated with peramivir plus two or more
other antivirals [e.g. oseltamivir and amantadine (1), oseltamivir
and inhaled zanamivir (1), oseltamivir and rimantadine (2), and
amantadine and ribavirin (1)]. Fifty-one cases had information
available on timing of oseltamivir and peramivir treatment: 14
(28%) received oseltamivir prior to initiation of peramivir, and 37
(73%) received concurrent administration of oseltamivir and
peramivir for least 24 hours; the median time for concurrent
administration of both drugs was one day (range 1–14); 19 (51%)
of these 37 died. The median number of days from illness onset to
starting treatment with an oral NAI or IV peramivir were 4 days
(range 0–23) and 9 days (range 2–38), respectively. The most
common reasons cited in the medical records for initiation of
peramivir included ‘‘not responding to oral or inhaled antivirals’’
(43; 75%) followed by ‘‘suspected malabsorption’’ (7; 12%).
The median age of peramivir recipients was 40 years (range
5 months-81 years). Fifty-six of 57 (98%) received antibiotic
treatment at admission to the hospital. Almost all (55; 96%) had
radiographic evidence of pneumonia with 54 (95%) requiring
mechanical ventilation. Fifty-three cases had information on dates
of antiviral treatment: 34 (64%) required vasopressor support for
hypotension associated with sepsis and 19 (36%) had new onset
acute renal failure requiring hemodialysis. Fourteen (25%) had
microbiologic evidence of community-acquired bacterial co-
infection at admission. The median length of hospital stay was
21 days (range 3–78).
Twenty-nine (51%) peramivir recipients died. Fatal peramivir
recipients differed from non-fatal peramivir recipients by being
more likely to be diagnosed with acute renal failure requiring
hemodialysis (p=0.02), to have a shorter length of hospital stay
(median 16 days vs. 31 days; p=0.002) and to receive peramivir
for a shorter duration (7 days vs. 9 days; p=0.02). There was no
significant difference between time from onset of symptoms and
initiation of any antiviral treatment among fatal and non-fatal
peramivir recipients (Table 1).
We also compared the 57 peramivir recipients to the 1627 cases
in the ICU who were treated with other NAIs but did not receive
peramivir. There was no significant difference with regard to the
overall proportion with an ACIP co-morbid condition, although
cases treated with peramivir had a slightly higher prevalence of
obesity (p=0.04) and morbid obesity (p=0.02). Peramivir
recipients were more likely to be diagnosed with pneumonia/
ARDS (p=0.0002) or sepsis (p=,0.0001), to require mechanical
ventilation (p=,0.0001) and to die (p=,0.0001). Both perami-
vir and non-peramivir recipients were initiated on NAIs within
similar timeframes [median 4 days (range 0–23) and 4 days (range
0–52), respectively; p=0.6].
Discussion
Our report adds to the limited existing data on use of the
investigational drug peramivir in hospitalized and critically ill
influenza patients. Two small case-series have described use of
multi-dose peramivir during the pH1N1 pandemic; one study of
31 critically ill adults and children conducted prior to the EUA
found a 56-day mortality of 41% (59% survival) [6], while another
report of 41 cases identified from multi-site hospitalization data
reported 27% mortality [7]. Clinical trials in hospitalized seasonal
influenza patients found no significant difference in treatment
outcome between five day courses of peramivir and either placebo
or oseltamivir [8]. The same has been found in the outpatient
setting; in clinical trials of over 1000 healthy adults treated with
either a single infusion of peramivir or a five day course of oral
oseltamivir, no difference was found in duration of symptoms
(peramivir recipients had decreased viral shedding) [9]. In our
series, over half of peramivir-treated cases died despite prolonged
antiviral treatment and aggressive supportive measures. Critically
ill cases who received peramivir were more likely to die than those
who did not receive peramivir.
The case fatality proportion (51%) in our pH1N1 patient
population was higher than that reported in other peramivir case
series, but comparisons are impeded by the limited clinical data
available. Of note, the 57 patients in our study were older (median
age of 40 vs. 23 years) and had a higher prevalence of co-
morbidities (72% vs. 45%) than the 31 patients who received
peramivir prior to the EUA (overall 41% mortality) [6]. Likewise,
in a second study of 41 peramivir patients with 27% case fatality
[7], the patients in our study had a higher proportion of ICU
admission (100% vs. 93%), mechanical ventilation (95% vs. 90%),
chronic pulmonary disease (53% vs. 29%), diabetes (21% vs. 12%),
obesity (57% vs. 44%), and morbid obesity (46% vs. 17%) [7].
More data are needed to fully understand the impact of these
demographic and clinical differences on overall mortality.
The high case fatality proportion described in our patient
population may have been due to the progressive severity of illness;
the majority of requests for peramivir were for cases assessed by
the clinician as not responding to several days of oral oseltamivir
therapy and with signs of continued clinical deterioration.
However, it also raises concerns of adverse drug events specifically
due to peramivir. Most of the available safety data describes single-
dose use of peramivir in adult and pediatric outpatient popula-
tions; commonly reported adverse events have included diarrhea,
nausea, vomiting, and neutropenia [5,8,10]. Limited data are
available on tolerability of multiple-dose peramivir in critically ill
patients. Reassuringly, while the nature of our surveillance does
not allow for detailed review, none of the peramivir recipients in
the medical records we reviewed had adverse events, side effects or
fatality that was assessed by the clinician as being a result of
peramivir administration, including nine children and three
pregnant women. This is consistent with limited descriptive
reports from other institutions during the pandemic [6–7].
Additionally, in our series, 37 critically ill cases received
concurrent administration of oseltamivir and peramivir for more
than 24 hours, with over half dying. The pH1N1 pandemic
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2009–August 2010.
Variable
Received peramivir
1 (n=57) Fatal (n=29)
Non-fatal
(n=28) P-value
2
Demographics
Female sex 26 (46%) 12 (41%) 41.5 (0.42–77) NS
Median age (years) and range 40 (0.42–81)* 41 (10–81) 41.5 (0.42–77) NS
Race/ethnicity
3 NS
Hispanic 22 (39%) 12 (41%) 10 (36%)
White, Non-Hispanic 22 (39%) 9 (31%) 13 (46%)
Asian/Pacific Islander 4 (7%) 2 (7%) 2 (7%)
Black, Non-Hispanic 7 (12%) 5 (17%) 2 (7%)
Other 2 (4%) 1 (3%) 1 (4%)
Native American 0 (0%) 0 (0%) 0 (0%)
Unknown 00 0
ACIP Co-morbid conditions
3,4
Any ACIP comorbidity 41 (72%) 20 (69%) 21 (75%) NS
Chronic cardiac disease
5 15 (26%) 8 (28%) 7 (25%) NS
Chronic lung disease
6 30 (53%) 16 (55%) 14 (50%) NS
Asthma 13 (23%) 7 (24%) 6 (21%) NS
Metabolic disease
7 18 (32%) 11 (38%) 7 (25%) NS
Diabetes mellitus 12 (21%) 7 (24%) 5 (18%) NS
Renal Disease 7 (12%) 3 (10%) 4 (14%) NS
Neurologic disorder
8 3 (5%) 0 (0%) 3 (11%) NS
Immunosuppressive conditions
9 12 (21%) 7 (24%) 5 (18%) NS
Pregnant 3/26 (12%) 2/12 (17%) 1/14 (7%) NS
Obesity
10 26/46 (57%) 15/24 (63%) 11/22 (50%) NS
BMI $40 12/26 (46%) 8/15 (53%) 4/11 (36%) NS
Clinical complications and management
Pneumonia/ARDS 55 (96%) 29 (100%) 26 (93%) NS
Mechanical ventilation 54 (95%) 27 (93%) 27 (96%) NS
Sepsis requiring vasopressors
1 34/53 (64%) 21/28 (75%) 13/25 (52%) NS
Acute renal failure requiring hemodialysis 19/53 (36%) 14/28 (50%) 5/25 (20%) 0.023
ECMO 9/55 (16%) 5/28 (18%) 4/27 (15%) NS
Pulmonary embolus 1 (2%) 1 (3%) 0 (0%) NS
Secondary bacterial infection
11 14 (25%) 7 (24%) 7 (25%) NS
Death 29 (51%) 29 (100%) N/A N/A
Length of hospital stay in days, median (range) 21 (3–78) 16 (3–68) 31 (11–78) 0.002
Length of ICU stay in days, median (range) 12.5 (1–66) 12 (1–66) 13 (13–13) NS
Time from hospital admission to ICU in days, median (range) 0 (0–5) 0 (0–3) 0 (0–5) NS
Details of medical treatment, including antivirals
Steroids
1 36/52 (69%) 21/28 (75%) 15/24 (63%) NS
Intravenous Immunoglobulin (IVIG)
1 9/51 (18%) 4/27 (15%) 5/24 (21%) NS
Treated with peramivir and oseltamivir
12 56 (98%) 28 (97%) 28 (100%) NS
Treated with peramivir and double-dose oseltamivir
13 23/56 (41%) 8/28 (29%) 15 (54%) NS
Treated with peramivir plus two or more other antivirals
14 5 (9%) 4 (14%) 1 (4%) NS
Time from symptom onset to any antiviral treatment, in days, median (range)
3 4 (0–23) 5 (0–23) 4 (0–9) NS
Time on any antiviral treatment, in days, median (range)
3 13 (3–36) 12 (3–36) 13.5 (9–33) NS
Time from symptom onset to peramivir treatment, in days, median (range)
3 9 (2–38) 10 (2–36) 9 (2–38) NS
Time on peramivir treatment, in days, median (range)
3 8 (1–22) 7 (1–15) 9 (5–22) 0.0225
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could lead to emergence of resistant strains. Treatment with a
combination of two antiviral agents could theoretically offer the
advantages of additive effect, while decreasing severity of disease,
duration of viral shedding and risk of developing resistance.
However, because all drugs in the NAI class target the same
binding pocket, drug antagonism is also a concern. Recent reports
suggest that combination NAI therapy may be less effective than
monotherapy; in a randomized controlled trial of over 500
outpatients with pH1N1 influenza, treatment with concurrent oral
oseltamivir and inhaled zanamavir was associated with more side
effects (nausea and vomiting) and shedding of higher viral titers for
longer periods compared to those receiving either drug alone [11].
Another case-series describing 21 critically ill patients treated with
oseltamivir and IV zanamavir reported a 24% mortality and
prolonged viral shedding [12]. Until more data are available,
combination NAI therapy should be used with caution.
Some limitations are important to note. There was likely
underreporting of cases during the pH1N1 pandemic, including
those who received peramivir. While 57 cases were identified by
search of the CDPH surveillance database, during the same
timeframe the CDC received 130 requests for peramivir from
California [CDC, unpublished data.], suggesting that treatment
was not administered to many cases, due to clinical improvement,
death, or other reasons. Serial testing for influenza by PCR, which
might inform decisions on when to modify or cease antiviral
therapy, was not performed in our 57 peramivir recipients. It is
possible that some patients may have had poor outcomes following
peramivir treatment related to the presence of the H275Y
mutation in viral neuraminidase, which confers resistance to
oseltamivir and reduced in-vitro susceptibility to peramivir [13].
This is likely a rare event; during the period of this surveillance, of
2260 cases tested, only nine cases of infection with pH1N1 viruses
containing the H275Y mutation were identified in California
(CDPH, unpublished data).
In conclusion, current guidelines strongly recommend treatment
with oral oseltamivir as soon as possible in influenza patients who
are hospitalized, have ACIP-defined high risk conditions, or have
severe or progressive clinical presentation [14–15]. For critically ill
patients in the ICU, investigational IV NAIs such as peramivir or
IV zanamivir may be an option; both are available through
clinical trials (http://clinicaltrials.gov) and IV zanamivir is also
available on a compassionate use basis (http://www.
clinicalsupporthd.gsk.com/). However, while the high mortality
(.50%) we observed could be due to the pre-existing clinical
severity of cases prior to request for peramivir, it also raises
questions about peramivir safety and effectiveness in hospitalized
and critically ill patients. Although ours is the largest case-series
describing the use of peramivir in criticaly ill patients published to
date, the nature of our surveillance and the criteria for requesting
peramivir under EUA precludes any comparison of effectiveness
between the oral and IV NAIs. Large randomized clinical trials
are required to assess these questions appropriately among
hospitalized influenza patients, or, in the absence of data from
randomized controlled trials by use of methods such as propensity
scoring and matching to assess the clinical effectiveness and safety
of new investigational agents for influenza treatment.
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